{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:03:48Z","timestamp":1792800228187,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2020YFC2008305"],"award-info":[{"award-number":["2020YFC2008305"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Beijing Municipal Science and Technology Commission Special Funding Project","award":["D181100000218002"],"award-info":[{"award-number":["D181100000218002"]}],"id":[{"id":"https:\/\/ror.org\/034k14f91","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Beijing Municipal Science and Technology Commission Special Funding Project","award":["D181100000218002"],"award-info":[{"award-number":["D181100000218002"]}],"id":[{"id":"https:\/\/ror.org\/034k14f91","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Clinical Research Center for Geriatric Disorders, Beijing, China. Beijing Municipal Commission of Health and Family Planning","award":["PXM2018_026283_000002"],"award-info":[{"award-number":["PXM2018_026283_000002"]}]},{"name":"National Clinical Research Center for Geriatric Disorders, Beijing, China. Beijing Municipal Commission of Health and Family Planning","award":["PXM2018_026283_000002"],"award-info":[{"award-number":["PXM2018_026283_000002"]}]},{"name":"National Clinical Research Center for Geriatric Disorders, Beijing, China. Beijing Municipal Commission of Health and Family Planning","award":["PXM2018_026283_000002"],"award-info":[{"award-number":["PXM2018_026283_000002"]}]},{"name":"Beijing Municipal Administration of Hospitals Incubating Program","award":["PX2020038"],"award-info":[{"award-number":["PX2020038"]}],"id":[{"id":"https:\/\/ror.org\/04baakq55","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We investigated the associations between the different doses of tigecycline, its efficacy and safety, and the role of tigecycline therapeutic drug monitoring for patients in the intensive care unit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This study was a single-center cohort including patients infected with multidrug-resistant\n                      <jats:italic>Acinetobacter baumannii<\/jats:italic>\n                      \u00a0(MDR-AB) and multidrug-resistant\u00a0\n                      <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n                      \u00a0(MDR-KP) causing pulmonary infections. The steady-state plasma concentration after tigecycline administration was determined by High-Performance Liquid Chromatography (HPLC) in patients admitted to the ICU between October 2020 and December 2021. Multivariate analyses of tigecycline\u2019s clinical efficacy and safety were performed to control confounding factors.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      For this study, we included 45 patients and 45 blood samples to determine steady-state trough concentrations of tigecycline. All patients were divided into the High Dose (HD) and Standard Dose (SD) groups. The median trough concentration of tigecycline was 0.56\u00a0\u03bcg\/mL in the HD group, which was higher than in the SD group (0,21\u00a0\u03bcg\/mL),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.000. There was no significant difference between the two groups of patients in terms of bacterial eradication rate, mortality rate, and clinical efficacy. Multiple regression analysis showed that the ICU days were correlated with mortality OR 1.030(1.005\u20131.056),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.017. APACHE II was significantly associated with clinical efficacy OR 0.870(0.755\u20131.002),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.045. The level of fibrinogen decline in the HD group was significantly higher than in the SD group (-3.05\u2009\u00b1\u20091.67 vs -1.75\u2009\u00b1\u20091.90),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.038. We identified that age and tigecycline treatment duration influenced fibrinogen decline.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Tigecycline plasma concentrations are significantly increased when using a high dose. However, the plasma concentration of tigecycline is not correlated with clinical efficacy and adverse reactions. Fibrinogen decline appears to be related to the patient\u2019s age and days of tigecycline. Large sample data are still needed to confirm the clinical guidance significance of tigecycline TDM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-023-08815-7","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T03:01:53Z","timestamp":1701054113000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Clinical efficacy and safety of tigecycline based on therapeutic drug monitoring for carbapenem-resistant Gram-negative bacterium pneumonia in intensive care units"],"prefix":"10.1186","volume":"23","author":[{"given":"Xiang-rong","family":"Bai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-zhou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-chao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-gai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-chuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-ying","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,27]]},"reference":[{"key":"8815_CR1","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1086\/432803","volume":"41","author":"R Gaynes","year":"2005","unstructured":"Gaynes R, Edwards JR. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis. 2005;41:848\u201354.","journal-title":"Clin Infect Dis"},{"key":"8815_CR2","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa1914433","volume":"382","author":"JA Jernigan","year":"2020","unstructured":"Jernigan JA, Hatfield KM, Wolford H, et al. Multidrug-resistant bacterial infections in U.S. hospitalized patients, 2012\u20132017. N Engl J Med. 2020;382:1309\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1914433.","journal-title":"N Engl J Med"},{"key":"8815_CR3","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1086\/505494","volume":"43","author":"GE Stein","year":"2006","unstructured":"Stein GE, Craig WA. Tigecycline: a critical analysis. Clin Infect Dis. 2006;43:518\u201324.","journal-title":"Clin Infect Dis"},{"key":"8815_CR4","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.2165\/00003495-200565180-00008","volume":"65","author":"JE Frampton","year":"2005","unstructured":"Frampton JE, Curran MP. Tigecycline. Drugs. 2005;65:2623\u201335 discussion 2636\u20137.","journal-title":"Drugs"},{"key":"8815_CR5","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s12325-020-01235-y","volume":"37","author":"L Zha","year":"2020","unstructured":"Zha L, Pan L, Guo J, et al. Effectiveness and safety of high dose tigecycline for the treatment of severe infections: a systematic review and meta-analysis. Adv Ther. 2020;37:1049\u201364.","journal-title":"Adv Ther"},{"key":"8815_CR6","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/cid\/ciac268","volume":"75","author":"PD Tamma","year":"2022","unstructured":"Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America 2022 guidance on the treatment of extended-spectrum \u03b2-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clin Infect Dis. 2022;75:187\u2013212.","journal-title":"Clin Infect Dis"},{"key":"8815_CR7","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.jiac.2022.03.003","volume":"28","author":"T Ohashi","year":"2022","unstructured":"Ohashi T, Sugiyama N, Watanabe T, et al. Drug use investigation on the safety and efficacy of tigecycline in Japan (all-case post-marketing surveillance). J Infect Chemother. 2022;28:866\u201374.","journal-title":"J Infect Chemother"},{"key":"8815_CR8","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s00277-010-0911-7","volume":"89","author":"H Pieringer","year":"2010","unstructured":"Pieringer H, Schmekal B, Biesenbach G, et al. Severe coagulation disorder with hypofibrinogenemia associated with the use of tigecycline. Ann Hematol. 2010;89:1063\u20134.","journal-title":"Ann Hematol"},{"key":"8815_CR9","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ijantimicag.2014.07.014","volume":"45","author":"C Routsi","year":"2015","unstructured":"Routsi C, Kokkoris S, Douka E, et al. High-dose tigecycline-associated alterations in coagulation parameters in critically ill patients with severe infections. Int J Antimicrob Agents. 2015;45:90\u20133.","journal-title":"Int J Antimicrob Agents"},{"key":"8815_CR10","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12959-022-00369-z","volume":"20","author":"M Guo","year":"2022","unstructured":"Guo M, Liang J, Li D, et al. Coagulation dysfunction events associated with tigecycline: a real-world study from FDA adverse event reporting system (FAERS) database. Thromb J. 2022;20:12.","journal-title":"Thromb J"},{"key":"8815_CR11","doi-asserted-by":"publisher","first-page":"325","DOI":"10.2147\/TCRM.S302850","volume":"17","author":"J Liu","year":"2021","unstructured":"Liu J, Yan Y, Zhang F. Risk factors for tigecycline-associated hypofibrinogenemia. Ther Clin Risk Manag. 2021;17:325\u201332. https:\/\/doi.org\/10.2147\/TCRM.S302850.","journal-title":"Ther Clin Risk Manag"},{"key":"8815_CR12","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","volume":"46","author":"MH Abdul-Aziz","year":"2020","unstructured":"Abdul-Aziz MH, Alffenaar JC, Bassetti M, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper(). Intensive Care Med. 2020;46:1127\u201353.","journal-title":"Intensive Care Med"},{"key":"8815_CR13","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1097\/FTD.0000000000000784","volume":"42","author":"G Fan","year":"2020","unstructured":"Fan G, Jin L, Bai H, et al. Safety and efficacy of tigecycline in intensive care unit patients based on therapeutic drug monitoring. Ther Drug Monit. 2020;42:835\u201340.","journal-title":"Ther Drug Monit"},{"key":"8815_CR14","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1093\/cid\/ciw353","volume":"63","author":"AC Kalil","year":"2016","unstructured":"Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63:e61-61e111.","journal-title":"Clin Infect Dis"},{"key":"8815_CR15","first-page":"16","volume":"19","author":"LYW Wen-chao","year":"2022","unstructured":"Wen-chao LYW, Qian SSS, Xiao-ling LXB. Establishment and application of a HPLC method for determination of tigecycline in human serum. Chin J Drug Appl Monit. 2022;19:16\u201320.","journal-title":"Chin J Drug Appl Monit"},{"key":"8815_CR16","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s10096-020-04123-z","volume":"40","author":"D Yin","year":"2021","unstructured":"Yin D, Guo Y, Li M, et al. Performance of VITEK 2, E-test, Kirby-Bauer disk diffusion, and modified Kirby-Bauer disk diffusion compared to reference broth microdilution for testing tigecycline susceptibility of carbapenem-resistant K. pneumoniae and A. baumannii in a multicenter study in China. Eur J Clin Microbiol Infect Dis. 2021;40:1149\u201354.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"8815_CR17","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1248\/bpb.b13-00109","volume":"37","author":"SH Kwon","year":"2014","unstructured":"Kwon SH, Ahn HL, Han OY, et al. Efficacy and safety profile comparison of colistin and tigecycline on the extensively drug resistant Acinetobacter baumannii. Biol Pharm Bull. 2014;37:340\u20136.","journal-title":"Biol Pharm Bull"},{"key":"8815_CR18","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, et al. Using the common terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed). 2021;112:90\u20132.","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"issue":"4","key":"8815_CR19","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","volume":"28","author":"M Paul","year":"2022","unstructured":"Paul M, Carrara E, Retamar P, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect. 2022;28(4):521\u201347.","journal-title":"Clin Microbiol Infect"},{"key":"8815_CR20","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12941-017-0199-8","volume":"16","author":"J Wang","year":"2017","unstructured":"Wang J, Pan Y, Shen J, et al. The efficacy and safety of tigecycline for the treatment of bloodstream infections: a systematic review and meta-analysis. Ann Clin Microbiol Antimicrob. 2017;16:24.","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"8815_CR21","doi-asserted-by":"publisher","first-page":"e3126","DOI":"10.1097\/MD.0000000000003126","volume":"95","author":"W Ni","year":"2016","unstructured":"Ni W, Han Y, Liu J, et al. Tigecycline treatment for carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis. Medicine (Baltimore). 2016;95:e3126.","journal-title":"Medicine (Baltimore)"},{"key":"8815_CR22","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1111\/jcpt.13250","volume":"45","author":"Q Zhang","year":"2020","unstructured":"Zhang Q, Wang J, Liu H, et al. Risk factors for tigecycline-induced hypofibrinogenaemia. J Clin Pharm Ther. 2020;45:1434\u201341.","journal-title":"J Clin Pharm Ther"},{"key":"8815_CR23","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.ijantimicag.2016.12.008","volume":"49","author":"R Singh","year":"2017","unstructured":"Singh R, Mukker JK, Drescher SK, et al. A need to revisit clinical breakpoints of tigecycline: effect of atypical non-linear plasma protein binding. Int J Antimicrob Agents. 2017;49:449\u201355.","journal-title":"Int J Antimicrob Agents"},{"key":"8815_CR24","doi-asserted-by":"publisher","unstructured":"Shao R, Li X, Hu Y, et al. Determination of tigecycline in human plasma by LC-MS\/MS and its application to population pharmacokinetics study in Chinese patients with hospital-acquired pneumonia. Biomed Chromatogr. 2018;32. https:\/\/doi.org\/10.1002\/bmc.4045.","DOI":"10.1002\/bmc.4045"},{"key":"8815_CR25","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1111\/bcp.14692","volume":"87","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Xu P, Li H, et al. Population pharmacokinetics and exposure-response analysis of tigecycline in patients with hospital-acquired pneumonia. Br J Clin Pharmacol. 2021;87:2838\u201346.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"8815_CR26","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1080\/1120009X.2018.1425279","volume":"30","author":"XR Bai","year":"2018","unstructured":"Bai XR, Liu JM, Jiang DC, et al. Efficacy and safety of tigecycline monotherapy versus combination therapy for the treatment of hospital-acquired pneumonia (HAP): a meta-analysis of cohort studies. J Chemother. 2018;30(3):172\u20138.","journal-title":"J Chemother"},{"issue":"8","key":"8815_CR27","first-page":"903","volume":"10","author":"JM Park","year":"2021","unstructured":"Park JM, Yang KS, Chung YS, et al. Clinical outcomes and safety of meropenem-colistin versus meropenem-tigecycline in patients with carbapenem-resistant Acinetobacter baumannii pneumonia. Antibiotics (Basel, Switzerland). 2021;10(8):903.","journal-title":"Antibiotics (Basel, Switzerland)"},{"issue":"9","key":"8815_CR28","doi-asserted-by":"publisher","first-page":"5238","DOI":"10.1128\/AAC.00270-16","volume":"60","author":"Y Cai","year":"2016","unstructured":"Cai Y, Lim TP, Teo J, Sasikala S, et al. In Vitro activity of polymyxin B in combination with various antibiotics against extensively drug-resistant Enterobacter cloacae with decreased susceptibility to polymyxin B. Antimicrob Agents Chemother. 2016;60(9):5238\u201346.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"8815_CR29","first-page":"273","volume":"12","author":"L Zha","year":"2023","unstructured":"Zha L, Zhang X, Cheng Y, et al. Intravenous polymyxin B as adjunctive therapy to high-dose tigecycline for the treatment of nosocomial pneumonia due to carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae: a propensity score-matched cohort study. Antibiotics (Basel, Switzerland). 2023;12(2):273.","journal-title":"Antibiotics (Basel, Switzerland)"},{"issue":"4","key":"8815_CR30","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1007\/s40121-021-00542-3","volume":"10","author":"Y Shi","year":"2021","unstructured":"Shi Y, Hu J, Liu P, et al. Ceftazidime-avibactam-based versus tigecycline-based regimen for the treatment of carbapenem-resistant Klebsiella pneumoniae-induced pneumonia in critically ill patients. Infect Dis Ther. 2021;10(4):2721\u201334.","journal-title":"Infect Dis Ther"},{"issue":"1","key":"8815_CR31","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40360-019-0300-3","volume":"20","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Chen X, Xu P, et al. Clinical experience with tigecycline in the treatment of hospital-acquired pneumonia caused by multidrug resistant Acinetobacter baumannii. BMC Pharmacol Toxicol. 2019;20(1):19.","journal-title":"BMC Pharmacol Toxicol"},{"key":"8815_CR32","doi-asserted-by":"publisher","first-page":"115564","DOI":"10.1016\/j.biopha.2023.115564","volume":"167","author":"J Teng","year":"2023","unstructured":"Teng J, Imani S, Zhou A, et al. Combatting resistance: understanding multidrug resistant pathogens in intensive care units. Biomed Pharmacother. 2023;167:115564.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"8815_CR33","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s12866-023-02974-y","volume":"23","author":"J Yang","year":"2023","unstructured":"Yang J, Zhang K, Ding C, et al. Exploring multidrug-resistant Klebsiella pneumoniae antimicrobial resistance mechanisms through whole genome sequencing analysis. BMC Microbiol. 2023;23(1):245.","journal-title":"BMC Microbiol"},{"key":"8815_CR34","doi-asserted-by":"publisher","first-page":"5545","DOI":"10.2147\/IDR.S381280","volume":"15","author":"XR Bai","year":"2022","unstructured":"Bai XR, Cao JR, Wang ZZ, et al. Clinical efficacy, antibiotic resistance genes, virulence factors and outcome of hospital-acquired pneumonia induced by Klebsiella pneumoniae carbapenemase 2-producing with tigecycline treatment in the ICU. Infect Drug Resist. 2022;15:5545\u201355.","journal-title":"Infect Drug Resist"},{"key":"8815_CR35","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1128\/AAC.01615-10","volume":"56","author":"SM Bhavnani","year":"2012","unstructured":"Bhavnani SM, Rubino CM, Hammel JP, et al. Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline. Antimicrob Agents Chemother. 2012;56:1065\u201372.","journal-title":"Antimicrob Agents Chemother"},{"key":"8815_CR36","doi-asserted-by":"publisher","first-page":"761167","DOI":"10.3389\/fphar.2021.761167","volume":"12","author":"X Shi","year":"2021","unstructured":"Shi X, Zuo C, Yu L, et al. Real-world data of tigecycline-associated drug-induced liver injury among patients in China: a 3-year retrospective study as assessed by the updated RUCAM. Front Pharmacol. 2021;12:761167.","journal-title":"Front Pharmacol"},{"key":"8815_CR37","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1159\/000525380","volume":"107","author":"D Wang","year":"2022","unstructured":"Wang D, Lin C, Gu C, et al. Tigecycline-associated coagulopathy: a single-center retrospective analysis. Pharmacology. 2022;107:524\u201336.","journal-title":"Pharmacology"},{"key":"8815_CR38","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1007\/s11096-020-01072-7","volume":"42","author":"D Campany-Herrero","year":"2020","unstructured":"Campany-Herrero D, Larrosa-Garcia M, Lalueza-Broto P, et al. Tigecycline-associated hypofibrinogenemia in a real-world setting. Int J Clin Pharm. 2020;42:1184\u20139.","journal-title":"Int J Clin Pharm"},{"key":"8815_CR39","doi-asserted-by":"crossref","unstructured":"Levy JH, Welsby I, Goodnough LT. Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy. Transfusion. 2014;54:1389\u2013405; quiz 1388.","DOI":"10.1111\/trf.12431"},{"key":"8815_CR40","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1046\/j.1365-2141.1996.d01-1731.x","volume":"93","author":"M Vasse","year":"1996","unstructured":"Vasse M, Paysant I, Soria J, et al. Down-regulation of fibrinogen biosynthesis by IL-4, IL-10 and IL-13. Br J Haematol. 1996;93:955\u201361.","journal-title":"Br J Haematol"},{"issue":"431","key":"8815_CR41","first-page":"e1","volume":"24","author":"SJ Vandecasteele","year":"2018","unstructured":"Vandecasteele SJ, Seneca S, Smet J, et al. Tigecycline-induced inhibition of mitochondrial DNA translation may cause lethal mitochondrial dysfunction in humans. Clin Microbiol Infect. 2018;24(431):e1-431.e3.","journal-title":"Clin Microbiol Infect"},{"key":"8815_CR42","doi-asserted-by":"publisher","first-page":"e2212694120","DOI":"10.1073\/pnas.2212694120","volume":"120","author":"KO Tamadonfar","year":"2023","unstructured":"Tamadonfar KO, Di Venanzio G, Pinkner JS, et al. Structure-function correlates of fibrinogen binding by Acinetobacter adhesins critical in catheter-associated urinary tract infections. Proc Natl Acad Sci U S A. 2023;120:e2212694120.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8815_CR43","doi-asserted-by":"publisher","first-page":"942482","DOI":"10.3389\/fimmu.2022.942482","volume":"13","author":"JI Ries","year":"2022","unstructured":"Ries JI, He\u00df M, Nouri N, et al. CipA mediates complement resistance of Acinetobacter baumannii by formation of a factor I-dependent quadripartite assemblage. Front Immunol. 2022;13:942482.","journal-title":"Front Immunol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08815-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-023-08815-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08815-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T03:02:44Z","timestamp":1701054164000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-023-08815-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,27]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["8815"],"URL":"https:\/\/doi.org\/10.1186\/s12879-023-08815-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3140601\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,27]]},"assertion":[{"value":"5 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was carried out by the Declaration of Helsinki criteria and received approval from the Ethics Committee of Xuanwu Hospital Capital Medical University (IRB, protocol number: 2020038 6\/20\/2020). All methods were carried out in accordance with relevant guidelines and regulations. Informed consent was obtained from all study participants prior to the start of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"830"}}